ImmuneSensor Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ImmuneSensor Therapeutics is a private, clinical-stage biotech leveraging foundational IP from the discovery of the cGAS enzyme to develop first- and best-in-class inhibitors of the cGAS-STING pathway. The company's lead cGAS inhibitor, IMSB301, entered Phase 1 trials in 2024, while its STING agonist, IMSA101, has completed a Phase 1 trial in oncology. With a seasoned leadership team and a focus on orally available small molecules, ImmuneSensor aims to address significant unmet needs in autoimmunity, inflammation, and cancer.

Autoimmune DiseasesInflammatory DiseasesOncology

Technology Platform

Dual-platform targeting the cGAS-STING pathway: 1) Development of orally available small molecule cGAS inhibitors to suppress inflammation/autoimmunity. 2) Development of STING agonists (including an ADC platform) for cancer immunotherapy.

Opportunities

The cGAS inhibitor platform addresses a vast, underserved market in autoimmune and inflammatory diseases (e.g., lupus, arthritis) with a novel, targeted oral mechanism that could offer superior safety and efficacy versus broad immunosuppressants.

The STING agonist ADC platform offers a differentiated, tumor-targeted approach in the competitive immuno-oncology space, potentially improving therapeutic index.

Risk Factors

High clinical development risk: cGAS inhibition is a novel mechanism, and safety concerns regarding chronic immunosuppression of a key DNA-sensing pathway are untested in humans.

Intense and growing competition from large pharma and other bioteats in both the cGAS inhibitor and STING agonist spaces creates commercial and scientific hurdles.

Competitive Landscape

The cGAS/STING field is highly competitive. In cGAS inhibition, companies like Novartis, Ventus Therapeutics, and IFM Therapeutics are advancing programs. The STING agonist space is crowded with candidates from large pharma (e.g., Merck, GSK, AstraZeneca) and biotech, though ImmuneSensor's ADC approach may offer differentiation. ImmuneSensor's key competitive advantage is its foundational IP and deep expertise directly linked to the pathway's discoverer.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →